Jun Sugisaka

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Comparison of anthracycline plus platinum versus other platinum-based regimens as first-line chemotherapy for untreated thymoma: A retrospective cohort study (NEJ023B).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 29, 2026

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Journal: American journal of respiratory and critical care medicine

Published: January 25, 2026

Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study.

Prognostic Significance of Tumor-Cell VISTA Expression on Survival Outcomes in Nivolumab-Treated Pleural Mesothelioma: The HOT1901 Retrospective Multi-Institutional Study.

Journal: ImmunoTargets and therapy

Published: December 07, 2025

Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.

Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.

Journal: Journal of medical case reports

Published: November 28, 2025

Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.

Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.

Journal: Translational lung cancer research

Published: September 25, 2025

Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301.

Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301.

Journal: Translational lung cancer research

Published: July 17, 2025

A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.

A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.

Journal: IDCases

Published: June 16, 2025

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Journal: Translational lung cancer research

Published: May 31, 2025

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 13, 2025

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 22, 2024

Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).

Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).

Journal: Cancer science

Published: May 08, 2024

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.

Journal: Nature communications

Published: April 06, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026